A Comparative, Randomized, Open-label, Fasted, Single-dose, 2-way Crossover Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Opicapone (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Bial
- 24 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
- 24 Jul 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Apr 2017 New trial record